Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

In this podcast episode, experts Samuel Klempner, MD, and Gregory Botta, MD, PhD, discuss the rationale supporting claudin 18.2 as a therapeutic target and clinical considerations for related emerging therapies in the treatment of gastric and gastroesophageal cancers.